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Is Becker dystrophinopathy a contraindication to heart 
transplant?: experience in a single institution 
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To the Editor, 
 
Becker dystrophinopathy is an X-linked inherited disease caused by a mutation in the Xp21 
gene, which encodes dystrophin.
1
 Dystrophin is expressed in both skeletal and cardiac muscle, and 
the disease can thus feature myopathic and cardiovascular symptoms. 
 
Clinical manifestations generally appear in the second decade of life and usually begin with 
muscle weakness in the pelvic girdle.
2
 Cardiac involvement is an infrequent manifestation, but 
affects some patients.
3,4





Becker dystrophinopathy patients with refractory heart failure are candidates for heart 
transplant (HTx), but there is some debate about the suitability of this procedure.
1,3,4 
The main 
concerns about HTx for Becker dystrophinopathy patients are the potential perioperative risk, the 
risk that HTx might exclude patients from subsequent respiratory physiotherapy and motor 
rehabilitation, and the risk that post-HTx corticosteroid therapy will trigger myopathy progression. 
This article presents a single-center experience with a small series of Becker dystrophinopathy 
patients with dilated cardiomyopathy who underwent HTx. 
  
From 1991 to 2017, 781 patients received HTx at the study center. Of these patients, 6 (0.8%) 
had a diagnosis of dilated cardiomyopathy associated with Becker muscular dystrophy. The 
baseline clinical characteristics of these patients are summarized in Table 1. 
Table 1. Baseline Characteristics 
Patient Sex Age at NMD onset, y Age at HF onset, y Age at HTx, y Pre-HTx CK, IU/L Follow-up, mo 
       
1 Male 9 41 44 37 230 
2 Male 4 20 24 775 159 
3 Male 12 35 43 416 91 
4 Male 15 30 36 257 77 
5 Male 28 35 44 445 12 
6 Male 46 30 48 342 10 
       
 
CK, creatine kinase; HF, heart failure; HTx, heart transplant; NMD, neuromuscular disease. 
The median age of patients at the time of dystrophinopathy diagnosis was 13.5 years. Clinical 
manifestation of heart failure occurred at a median age of 32.5 years, and patients underwent HTx 
at a median age of 43.5 years. HTx was an emergency procedure in 4 patients (67%). At the time 
of inclusion on the waiting list, all patients had mild muscle damage and complete functional 
autonomy, with no significant respiratory involvement. 
 
All the patients received immunosuppressive therapy with calcineurin inhibitors (cyclosporine 
or tacrolimus) and mycophenolate mofetil, except for 1 patient who received azathioprine. All 
patients were placed on indefinite corticosteroid therapy, with the dose reduced as much as 
possible from the sixth month post-HTx (target prednisone maintenance dose ≤5 mg/d). Statin 
therapy was prescribed in all patients but was withdrawn in 2 patients (33.3%) due to muscle 
toxicity featuring marked elevation of serum creatine kinase. 
 
In the immediate postoperative period, 3 patients (50%) developed acute renal failure requiring 
dialysis. In the same period, 2 patients (33%) developed posterior reversible encephalopathy 
syndrome linked to calcineurin inhibitors, and 1 patient (17%) developed severe resistant 
hypertension. Extubation was performed within 24 hours of surgery in 2 of the 6 patients (33%) 
and was maintained for between 5 and 13 days after transplant surgery in the remaining 4 patients. 
There were no instances of immediate postoperative death or episodes of early transplant 
dysfunction requiring mechanical circulation support. 
 
All patients had long-term survival after HTx over a mean 96-month follow-up (range, 10-230 
months). At the time of writing, there has been only 1 death, due to lung cancer and occurring 19 
years after the transplant surgery. Transplanted organ function is conserved in the 5 surviving 
patients, and to date there have been no episodes of transplant rejection with hemodynamic 
deterioration. Slow post-HTx progression of muscle damage has resulted in 3 patients needing a 
wheelchair for mobility. 
 
The medical literature contains few reports of Becker muscular dystrophy patients undergoing 
HTx; however, the little available evidence indicates that these patients have similar long-term 




The results observed in this cohort of heart transplant recipients with Becker dystrophinopathy 
are satisfactory, with long-term survival and good functional prognosis indicating well-tolerated 
immunosuppressive therapy. HTx thus appears to be a valid option for Becker dystrophinopathy 
patients with refractory heart failure who show relatively preserved extracardiac muscle function 
before the intervention. 
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